AZD9291 in Combination With Ascending Doses of Novel Therapeutics
Running, not enrolling · Phase 1
Conditions studied: Advanced Non Small Cell Lung Cancer
In brief
The purpose of this study is to determine the safety, tolerability and preliminary anti-tumour activity of AZD9291 when given together with AZD6094 or selumetinib in patients with EGFR mutation positive advanced lung cancer
Key facts
- Study ID
- NCT02143466
- Run by
- AstraZeneca
- People needed
- 344
- Starts
- 2014-08-05
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2026-07-20
Who can join
Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Atlanta, Georgia, United States
- Research Site — Boston, Massachusetts, United States
- Research Site — Boston, Massachusetts, United States
- Research Site — New York, New York, United States
- Research Site — Philadelphia, Pennsylvania, United States
- Research Site — Nashville, Tennessee, United States
- Research Site — Calgary, Alberta, Canada
- Research Site — Edmonton, Alberta, Canada
- Research Site — Chūōku, Japan
- Research Site — Habikino-shi, Japan
- Research Site — Hirakata-shi, Japan
- Research Site — Kashiwa, Japan
- Research Site — Nagoya, Japan
- Research Site — Nagoya, Japan
- Research Site — Gdansk, Poland
- Research Site — Krakow, Poland
- Research Site — Olsztyn, Poland
- Research Site — Poznan, Poland
- Research Site — Warsaw, Poland
- Research Site — Chelyabinsk, Russia
- Research Site — Krasnoyarsk, Russia
- Research Site — Moscow, Russia
- Research Site — Omsk, Russia
- Research Site — Saint Petersburg, Russia
- Research Site — Saint Petersburg, Russia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.